Of the antidiabetic agents, metformin, pioglitazone, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and dipeptidyl-peptidase-4 inhibitors (DPP-4Is) have been shown to have favorable effects on NAFLD [119,120]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.